免疫评分系统在胃癌中的研究进展

doi:10.3760/cma.j.cn371439-20250509-00009

国际肿瘤学杂志 ›› 2026, Vol. 53 ›› Issue (1): 62-64.doi: 10.3760/cma.j.cn371439-20250509-00009

• 综述 • 上一篇

免疫评分系统在胃癌中的研究进展

王雨¹, 李袁飞²(), 郭云童³

¹山西医科大学第一临床医学院，太原 030001
²山西医科大学第一医院肿瘤消化科，太原 030001
³山西医科大学第一医院胃肠外科，太原 030001

收稿日期:2025-05-09 出版日期:2026-01-08 发布日期:2026-01-13
通讯作者: 李袁飞，Email： liyflinda@163.com
基金资助:
山西省基础研究计划(202303021211200)

Research progress of the immunoscore system in gastric cancer

Wang Yu¹, Li Yuanfei²(), Guo Yuntong³

¹First Clinical College of Shanxi Medical University， Taiyuan 030001， China
²Department of Oncology and Digestive Medicine， First Hospital of Shanxi Medical University， Taiyuan 030001， China
³Department of Gastrointestinal Surgery， First Hospital of Shanxi Medical University， Taiyuan 030001， China

Received:2025-05-09 Online:2026-01-08 Published:2026-01-13
Supported by:
Basic Research Program of Shanxi Province of China(202303021211200)

摘要/Abstract

摘要：

免疫评分系统作为评估肿瘤患者免疫状态和预后的关键指标，其预后评估及疗效预测作用在多种实体瘤中得以验证。胃癌免疫评分受肿瘤微环境、患者自身免疫状态等多因素的影响，总结其在预后预测、辅助治疗方案选择及疗效预测中的应用进展，可为胃癌的个体化治疗提供新的思路和见解。

关键词: 胃肿瘤, 肿瘤微环境, 免疫疗法

Abstract:

The immunoscore system serves as a key indicator for evaluating the immune status and prognosis of cancer patients. Its prognostic evaluation and efficacy prediction function have been validated in various solid tumors. The immunoscore in gastric cancer is modulated by various factors, including the tumor microenvironment and the patient's intrinsic immune status. A comprehensive summary of its applications in prognosis prediction, selection of adjuvant therapeutic regimens, and treatment response assessment may offer novel perspectives and strategic guidance for the individualized management of gastric cancer.

Key words: Stomach neoplasms, Tumor microenvironment, Immunotherapy

王雨, 李袁飞, 郭云童. 免疫评分系统在胃癌中的研究进展[J]. 国际肿瘤学杂志, 2026, 53(1): 62-64.

Wang Yu, Li Yuanfei, Guo Yuntong. Research progress of the immunoscore system in gastric cancer[J]. Journal of International Oncology, 2026, 53(1): 62-64.

参考文献 26

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	宫英博, 朱志, 王鑫, 等. 不同生物学行为对相同TNM分期进展期胃癌患者预后的影响[J]. 中华胃肠外科杂志, 2020, 23(10): 953-962. DOI: 10.3760/cma.j.cn.441530-20190926-00361.
[3]	Imen H, Amira H, Fatma K, et al. Prognostic value of immunoscore in colorectal carcinomas[J]. Int J Surg Pathol, 2024, 32(1): 58-65. DOI: 10.1177/10668969231168357.
[4]	Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy[J]. Nat Rev Cancer, 2020, 20(11): 662-680. DOI: 10.1038/s41568-020-0285-7.
[5]	Mastracci L, Fontana V, Queirolo P, et al. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4⁺ tumor infiltrating lymphocytes and their in situ localization[J]. Cancer Immunol Immunother, 2020, 69(4): 653-662. DOI: 10.1007/s00262-020-02494-y. pmid: 32025849
[6]	Bieri U, Enderlin D, Buser L, et al. Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: a digital pathology study[J]. Front Oncol, 2022, 12: 964672. DOI: 10.3389/fonc.2022.964672.
[7]	Li G, Song Q, Cai A, et al. An immunoscore nomogram for predicting survival in patients with oesophageal cancer[J]. Aging (Albany NY), 2021, 13(6): 8762-8776. DOI: 10.18632/aging.202686.
[8]	Zhang L, Dong Q, Wang Y, et al. Global trends and risk factors in gastric cancer: a comprehensive analysis of the Global Burden of Disease Study 2021 and multi-omics data[J]. Int J Med Sci, 2025, 22(2): 341-356. DOI: 10.7150/ijms.104437. pmid: 39781526
[9]	Jiang Y, Zhang Q, Hu Y, et al. Immunoscore signature: a prognostic and predictive tool in gastric cancer[J]. Ann Surg, 2018, 267(3): 504-513. DOI: 10.1097/SLA.0000000000002116. pmid: 28002059
[10]	Jiang Y, Wang H, Wu J, et al. Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer[J]. Ann Oncol, 2020, 31(6): 760-768. DOI: 10.1016/j.annonc.2020.03.295. pmid: 32240794
[11]	Zhao R, Shen W, Zhao W, et al. Integrating radiomics, pathomics, and biopsy-adapted immunoscore for predicting distant metastasis in locally advanced rectal cancer[J]. ESMO Open, 2025, 10(3): 104102. DOI: 10.1016/j.esmoop.2024.104102.
[12]	El Sissy C, Kirilovsky A, Van den Eynde M, et al. A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy[J]. Clin Cancer Res, 2020, 26(19): 5198-5207. DOI: 10.1158/1078-0432.CCR-20-0337. pmid: 32669377
[13]	曾强. 新辅助直肠评分及活检免疫评分在直肠癌不同新辅助放化疗模式中的价值[D]. 北京: 中国医学科学院, 2023. DOI: 10.27648/d.cnki.gzxhu.2023.000336.
[14]	Ghiringhelli F, Bibeau F, Greillier L, et al. Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti-PD1/PD-L1 immunotherapy in non-small cell lung cancer[J]. EBioMedicine, 2023, 92: 104633. DOI: 10.1016/j.ebiom.2023.104633.
[15]	Kim H, Heo YJ, Cho YA, et al. Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer[J]. Clin Transl Oncol, 2022, 24(3): 556-567. DOI: 10.1007/s12094-021-02714-6.
[16]	Yun S, Koh J, Nam SK, et al. Immunoscore is a strong predictor of survival in the prognosis of stage Ⅱ/Ⅲ gastric cancer patients following 5-FU-based adjuvant chemotherapy[J]. Cancer Immunol Immunother, 2021, 70(2): 431-441. DOI: 10.1007/s00262-020-02694-6.
[17]	Tan J, Wu Z, Liu Y, et al. Transcriptional profiling reveals H. pylori-associated genes induced inflammatory cell infiltration and chemoresistance in gastric cancer[J]. Front Immunol, 2025, 16: 1592558. DOI: 10.3389/fimmu.2025.1592558.
[18]	刘畅. 胃癌免疫评分与Tregs、PD-L1、MMR相关性及Tregs与免疫疗效关系探讨[D]. 承德: 承德医学院, 2023. DOI: 10.27691/d.cnki.gcdyx.2023.000027.
[19]	Yan H, Chen Y, Yang Z, et al. An immune cell signature is associated with disease-free survival and adjuvant chemosensitivity of patients with resectable gastric cancer[J]. Front Immunol, 2020, 11: 621623. DOI: 10.3389/fimmu.2020.621623.
[20]	Zeng D, Zhou R, Yu Y, et al. Gene expression profiles for a prognostic immunoscore in gastric cancer[J]. Br J Surg, 2018, 105(10): 1338-1348. DOI: 10.1002/bjs.10871. pmid: 29691839
[21]	Soeratram TTD, Beentjes I, Egthuijsen JMP, et al. A biopsy-based immunoscore in patients with treatment-naïve resectable gastric cancer[J]. Ther Adv Med Oncol, 2024, 16: 17588359241287747. DOI: 10.1177/17588359241287747.
[22]	Nie RC, Chen GM, Yuan SQ, et al. Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: systematic review and meta-analysis[J]. Ann Surg Oncol, 2022, 29(4): 2324-2331. DOI: 10.1245/s10434-021-11050-6.
[23]	Dang Y, Ma M, Wang Y, et al. Carvedilol sensitizes chemotherapy by targeting STING to boost anti-tumor immunity[J]. Cell Rep, 2025, 44(5): 115572. DOI: 10.1016/j.celrep.2025.115572.
[24]	Chen T, Li X, Mao Q, et al. An artificial intelligence method to assess the tumor microenvironment with treatment outcomes for gastric cancer patients after gastrectomy[J]. J Transl Med, 2022, 20(1): 100. DOI: 10.1186/s12967-022-03298-7.
[25]	Zeng D, Li M, Zhou R, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures[J]. Cancer Immunol Res, 2019, 7(5): 737-750. DOI: 10.1158/2326-6066.CIR-18-0436. pmid: 30842092
[26]	杨鹏, 罗金梅, 罗萍, 等. 基于免疫细胞浸润的免疫评分模型预测早期胃癌免疫治疗效果及预后[J]. 实用肿瘤学杂志, 2024, 38(2): 121-130. DOI: 10.11904/j.issn.1002-3070.2024.02.007.

免疫评分系统在胃癌中的研究进展

Research progress of the immunoscore system in gastric cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵元, 姚文涛. 恶性肿瘤新辅助免疫治疗的现状与挑战[J]. 国际肿瘤学杂志, 2026, 53(1): 47-52.
[2]	李婷, 周琦, 张倩, 陈洁. 晚期非小细胞肺癌抗PD-1/PD-L1治疗耐药机制的研究进展[J]. 国际肿瘤学杂志, 2026, 53(1): 57-61.
[3]	刘美, 胡玉崇, 李凤桐, 朝乐门, 柳檬, 亢琳琳. SHCBP1在恶性肿瘤中的作用机制及临床研究进展[J]. 国际肿瘤学杂志, 2025, 52(9): 583-586.
[4]	澈根, 乌日汗, 朱恬恬, 东丽. 非小细胞肺癌中cGAS-STING信号通路的作用机制及其靶向治疗策略[J]. 国际肿瘤学杂志, 2025, 52(9): 587-591.
[5]	宋美娇, 张锡泉, 沈庆林. 原发灶不明的转移性癌1例并文献复习[J]. 国际肿瘤学杂志, 2025, 52(9): 606-608.
[6]	李广鑫, 权慧娟, 高志娟, 王肖君, 李良, 董谦, 苗永涛, 刘东生. 血清HAMP、SPP1、RGS2水平与胃癌患者临床病理特征的相关性及对术后复发或转移的预测价值[J]. 国际肿瘤学杂志, 2025, 52(8): 502-507.
[7]	吴学慧, 李松, 刘联. TCR测序在肿瘤免疫治疗中的临床应用[J]. 国际肿瘤学杂志, 2025, 52(8): 523-527.
[8]	王旻, 温馨格, 魏毓正, 孙诚诚, 周婷婷. 纳武利尤单抗联合化疗治疗胃癌假性进展1例并文献复习[J]. 国际肿瘤学杂志, 2025, 52(6): 395-397.
[9]	孙玉娇, 于美丽, 马文静, 孙龙美, 朱兆峰, 郑媛媛. 可切除局部晚期食管鳞状细胞癌新辅助免疫治疗的临床应用进展[J]. 国际肿瘤学杂志, 2025, 52(5): 309-314.
[10]	刘海燕, 张超. 基于CT影像加权组学评分构建非小细胞肺癌的免疫治疗疗效预测模型[J]. 国际肿瘤学杂志, 2025, 52(4): 202-208.
[11]	刘前怡, 董洪敏, 王文玲, 王刚, 陈望花. 放疗联合化疗和免疫治疗对HER2阴性局部晚期或晚期胃癌的临床疗效和安全性[J]. 国际肿瘤学杂志, 2025, 52(4): 209-216.
[12]	文英美, 夏锦雄, 王园园, 姚颐. 放疗对抗肿瘤免疫的影响：从基础到临床[J]. 国际肿瘤学杂志, 2025, 52(4): 231-236.
[13]	王智颖, 盛立军. 外周血标志物在非小细胞肺癌免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(3): 180-185.
[14]	王熙博, 田宝文, 陈士巧. Breg细胞在肿瘤免疫逃逸中的机制及相关治疗靶点[J]. 国际肿瘤学杂志, 2025, 52(2): 107-112.
[15]	叶永英, 邹艳, 陈天明, 吴伟莉. 时钟基因Period家族在头颈鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(2): 113-118.